Literature DB >> 11124054

Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells.

R Abdul-Ghani1, P Ohana, I Matouk, S Ayesh, B Ayesh, M Laster, O Bibi, H Giladi, K Molnar-Kimber, M A Sughayer, N de Groot, A Hochberg.   

Abstract

Telomerase (hTER and hTERT) plays a crucial role in cellular immortalization and carcinogenesis. Telomerase activity can be detected in about 85% of different malignant tumors, but is absent in most normal cells. In situ hybridization analysis showed that high levels of hTER and hTERT expression are present in bladder cancer, while no signal was detected in normal tissue. Therefore, in this work we propose to use hTER and hTERT transcriptional regulatory sequences to control the expression of a cytotoxic gene in bladder tumor cells, resulting in the selective destruction of this cell population. Expression vectors containing the diphtheria toxin A-chain (DT-A) gene were linked to hTER and hTERT transcriptional regulatory sequences, respectively. Inhibition of protein synthesis occurred in bladder and hepatocellular carcinoma cells transfected with the plasmids containing the DT-A gene under the control of the hTER or hTERT promoters in correlation with their activity. These studies support the feasibility of using hTER and hTERT transcriptional regulatory sequences for targeted patient-oriented gene therapy of human cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124054     DOI: 10.1006/mthe.2000.0196

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  22 in total

1.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

Review 2.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 3.  Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology.

Authors:  J Fajkus; M Simícková; J Maláska
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

4.  Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.

Authors:  C-Q Su; J Sham; H-B Xue; X-H Wang; D Chua; Z-F Cui; L-H Peng; L-F Li; L-H Jiang; M-C Wu; Q-J Qian
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-09       Impact factor: 4.553

5.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 6.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 7.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

8.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

Review 9.  Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.

Authors:  Bijay Dhungel; Aparna Jayachandran; Christopher J Layton; Jason C Steel
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Use of the comet-FISH assay to compare DNA damage and repair in p53 and hTERT genes following ionizing radiation.

Authors:  Declan J McKenna; Bernadette A Doherty; C Stephen Downes; Stephanie R McKeown; Valerie J McKelvey-Martin
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.